Bandaríkin - enska - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - protriptyline hydrochloride (unii: 44665v00o8) (protriptyline - unii:4ndu154t12) - protriptyline hydrochloride 5 mg - protriptyline hydrochloride is indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. its activating properties make it particularly suitable for withdrawn and anergic patients. protriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with a monoamine oxidase inhibiting compound. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. protriptyline hydrochloride is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions including prol

Bandaríkin - enska - NLM (National Library of Medicine)

hi-tech pharmacal co., inc. - protriptyline hydrochloride (unii: 44665v00o8) (protriptyline - unii:4ndu154t12) - protriptyline hydrochloride 5 mg - protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. its activating properties make it particularly suitable for withdrawn and anergic patients. protriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with a monoamine oxidase inhibiting compound. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. protriptyline is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions includ

Bandaríkin - enska - NLM (National Library of Medicine)

epic pharma, llc - protriptyline hydrochloride (unii: 44665v00o8) (protriptyline - unii:4ndu154t12) - protriptyline hydrochloride 5 mg - protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. its activating properties make it particularly suitable for withdrawn and anergic patients. protriptyline hydrochloride tablets are contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with a monoamine oxidase inhibiting compound. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to substitute protriptyline for a monoamine oxidase inhibitor, a minimum of 14 days should be allowed to elapse after the latter is discontinued. protriptyline should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. protriptyline is contraindicated in patients taking cisapride because of the possibility of adverse cardiac interactions including prolongation of the qt interval, cardiac arrhythmias and conduction system disturbances. this drug should not be used during the acute recovery phase following myocardial infarction.

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - amitriptyline hydrochloride - oral tablet - 25mg

Bandaríkin - enska - NLM (National Library of Medicine)

advanced rx pharmacy of tennessee, llc - amitriptyline hydrochloride (unii: 26lud4jo9k) (amitriptyline - unii:1806d8d52k) - for the relief of symptoms of depression. endogenous depression is more likely to be alleviated than are other depressive states. amitriptyline hydrochloride is contraindicated in patients who have shown prior hypersensitivity to it. it should not be given concomitantly with monoamine oxidase inhibitors. hyperpyretic crises, severe convulsions, and deaths have occurred in patients receiving tricyclic antidepressant and monoamine oxidase inhibiting drugs simultaneously. when it is desired to replace a monoamine oxidase inhibitor with amitriptyline hydrochloride, a minimum of 14 days should be allowed to elapse after the former is discontinued. amitriptyline hydrochloride should then be initiated cautiously with gradual increase in dosage until optimum response is achieved. amitriptyline hydrochloride should not be given with cisapride due to the potential for increased qt interval and increased risk for arrhythmia. this drug is not recommended for use during the acute recovery phase following myocardial infarc

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

lexon (uk) ltd - nortriptyline hydrochloride - oral tablet - 25mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - nortriptyline hydrochloride - oral tablet - 10mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - nortriptyline hydrochloride - oral tablet - 25mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - nortriptyline hydrochloride - oral tablet - 25mg

Bretland - enska - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - nortriptyline hydrochloride - oral tablet - 10mg